Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jane F Apperley

Showing results (61-70 of 195) with videos related to

Pageof 20
Sort By:
Ejhaem|October 6, 2025
Changes in Common Blood Parameters After Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid LeukaemiaFiona Fernando, Claudia Wasko, Bronwen Johns, et al.
Blood|March 7, 2008
The effects of imatinib on pregnancy outcomeSeonaid M Pye, Jorge Cortes, Patricia Ault, et al.
Leukemia & Lymphoma|June 12, 2019
Blast crisis of chronic myeloid leukemia with plasmacytoid dendritic cell phenotype associated with a rare fusion transcript, e13a3 BCR-ABL1Danmei Xu, Simone Claudiani, Kikkeri Naresh, et al.
Haematologica|May 6, 2010
Primary plasma cell leukemia and autologous stem cell transplantationMary B Drake, Simona Iacobelli, Anja van Biezen, et al.
British Journal of Haematology|January 7, 2022
The UK SPIRIT 1 trial in newly diagnosed chronic myeloid leukaemiaPaolo Gallipoli, Richard E Clark, Jenny Byrne, et al.
British Journal of Haematology|August 26, 2004
Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS)Marianna Politou, Evangelos Terpos, Athanasios Anagnostopoulos, et al.
Cancer|March 24, 2005
Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinibDavid Marin, Jaspal S Kaeda, Catharina Andreasson, et al.
International Journal of Molecular Sciences|April 14, 2026
A Novel CIP2A and BCL-XL Clinical Diagnostic Toolkit to Predict Disease Progression and Treatment-Free Remission in Chronic Myeloid LeukaemiaAmmar A Basabrain, Gemma M Austin, Alison K Holcroft, et al.
Journal of Hematology & Oncology|December 28, 2018
Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel reviewJorge E Cortes, Jane F Apperley, Daniel J DeAngelo, et al.
Blood|October 6, 2007
Philadelphia-negative clonal hematopoiesis is a significant feature of dasatinib therapy for chronic myeloid leukemiaValeria A S De Melo, Dragana Milojkovic, Jamshid S Khorashad, et al.
Pageof 20

Showing results (61-70 of 195) with videos related to

Sort By:
Pageof 20
Ejhaem|October 6, 2025
Changes in Common Blood Parameters After Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid LeukaemiaFiona Fernando, Claudia Wasko, Bronwen Johns, et al.
Blood|March 7, 2008
The effects of imatinib on pregnancy outcomeSeonaid M Pye, Jorge Cortes, Patricia Ault, et al.
Leukemia & Lymphoma|June 12, 2019
Blast crisis of chronic myeloid leukemia with plasmacytoid dendritic cell phenotype associated with a rare fusion transcript, e13a3 BCR-ABL1Danmei Xu, Simone Claudiani, Kikkeri Naresh, et al.
Haematologica|May 6, 2010
Primary plasma cell leukemia and autologous stem cell transplantationMary B Drake, Simona Iacobelli, Anja van Biezen, et al.
British Journal of Haematology|January 7, 2022
The UK SPIRIT 1 trial in newly diagnosed chronic myeloid leukaemiaPaolo Gallipoli, Richard E Clark, Jenny Byrne, et al.
British Journal of Haematology|August 26, 2004
Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS)Marianna Politou, Evangelos Terpos, Athanasios Anagnostopoulos, et al.
Cancer|March 24, 2005
Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinibDavid Marin, Jaspal S Kaeda, Catharina Andreasson, et al.
International Journal of Molecular Sciences|April 14, 2026
A Novel CIP2A and BCL-XL Clinical Diagnostic Toolkit to Predict Disease Progression and Treatment-Free Remission in Chronic Myeloid LeukaemiaAmmar A Basabrain, Gemma M Austin, Alison K Holcroft, et al.
Journal of Hematology & Oncology|December 28, 2018
Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel reviewJorge E Cortes, Jane F Apperley, Daniel J DeAngelo, et al.
Blood|October 6, 2007
Philadelphia-negative clonal hematopoiesis is a significant feature of dasatinib therapy for chronic myeloid leukemiaValeria A S De Melo, Dragana Milojkovic, Jamshid S Khorashad, et al.
Pageof 20